• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Amgen

Amgen

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. UPDATE: Bipartisan political squabbling over drug prices has already cost biotech companies $21 billion

    UPDATE: Bipartisan political squabbling over drug prices has already cost biotech companies $21 billion

  2. UPDATE: Why you might want to avoid these 30 -2-

    UPDATE: Why you might want to avoid these 30 -2-

  3. UPDATE: Why you might want to avoid these 30 dividend stocks

    UPDATE: Why you might want to avoid these 30 dividend stocks

  4. UPDATE: Why you might want to avoid these 30 -2-

    UPDATE: Why you might want to avoid these 30 -2-

  5. UPDATE: Why you might want to avoid these 30 dividend stocks

    UPDATE: Why you might want to avoid these 30 dividend stocks

  6. Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer

    Seres Therapeutics Strengthens Board of Directors with Appointment of Willard Dere, M.D., Former Amgen Chief Medical Officer

  7. UPDATE: Vertex stock rockets to record, boosting market cap by $8 billion

    UPDATE: Vertex stock rockets to record, boosting market cap by $8 billion

  8. Vertex shares soar 24% to all-time high on cystic fibrosis drug studies

    Vertex shares soar 24% to all-time high on cystic fibrosis drug studies

  9. UPDATE: Why you might want to avoid these 30 dividend stocks

    UPDATE: Why you might want to avoid these 30 dividend stocks

  10. UPDATE: Why you might want to avoid these 30 -2-

    UPDATE: Why you might want to avoid these 30 -2-

12345

©2017 Morningstar Advisor. All right reserved.